Details for New Drug Application (NDA): 021632

✉ Email this page to a colleague

NDA 021632 describes ERAXIS, which is a drug marketed by Vicuron Holdings and is included in one NDA. It is available from one supplier. Additional details are available on the ERAXIS profile page.

The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.

Summary for 021632

Tradename:	ERAXIS
Applicant:	Vicuron Holdings
Ingredient:	anidulafungin
Patents:	0

Pharmacology for NDA: 021632

Suppliers and Packaging for NDA: 021632

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632	NDA	Roerig	0049-0114	0049-0114-28	15 mL in 1 VIAL, SINGLE-USE (0049-0114-28)
ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632	NDA	Roerig	0049-0116	0049-0116-28	30 mL in 1 VIAL, SINGLE-USE (0049-0116-28)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INTRAVENOUS			Strength	50MG/VIAL
Approval Date:	Feb 17, 2006	TE:		RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INTRAVENOUS			Strength	100MG/VIAL
Approval Date:	Nov 14, 2006	TE:		RLD:	Yes

Expired US Patents for NDA 021632

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vicuron Holdings	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-002	Nov 14, 2006	5,965,525	⤷ Get Started Free
Vicuron Holdings	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-002	Nov 14, 2006	7,709,444	⤷ Get Started Free
Vicuron Holdings	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-001	Feb 17, 2006	5,965,525	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.